# Oral Testosterone for the Treatment of Hypogonadism

> **NCT01717768** · PHASE2 · COMPLETED · sponsor: **TesoRx Pharma, LLC** · enrollment: 130 (actual)

## Conditions studied

- Hypogonadism

## Interventions

- **DRUG:** TSX-002

## Key facts

- **NCT ID:** NCT01717768
- **Lead sponsor:** TesoRx Pharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2014-08
- **Final completion:** 2014-12
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2015-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01717768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01717768, "Oral Testosterone for the Treatment of Hypogonadism". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01717768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*